Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I pharmacokinetics and safety study of single-dose NMK02 in Japanese patients with prostate cancer
jRCT2031260166Phase 1Recruiting
- Sponsor
- Nihon Medi-Physics Co., Ltd.
- Start
- Jun 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fluorine-18 psma-1007 in prostate cancer (PCa), sponsored by Nihon Medi-Physics Co., Ltd. Primary endpoints: Time course changes in radioactivity concentration in blood and plasma, Radioactivity pharmacokinetic parameters in blood and plasma and 2 more. Started Jun 2026; status: recruiting.
02
Drugs
fluorine-18 psma-1007
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2031260166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260166.